Why the study?
Temporal changes in left ventricular structures and their prognostic impacts in patients with HFpEF were not well understood.
Cohort (n=2,698)
Hazard Ratio: 4.65 (95% CI 3.09–6.99)
p-value: p=<0.001
In HFpEF patients, dynamic progression to left ventricular enlargement with hypertrophy is associated with a significantly increased risk of cardiovascular death or heart failure admission.
Dynamic LV enlargement with hypertrophy may refine HFpEF risk stratification; leaves open whether targeted remodeling therapies improve outcomes.
AIMS: We aimed to examine temporal changes in left ventricular (LV) structures and their prognostic impacts in patients with heart failure (HF) and preserved ejection fraction (HFpEF). METHODS AND RESULTS: In the Chronic Heart Failure Analysis and Registry in the Tohoku District-2 (CHART-2) study (n = 10 219), we divided 2698 consecutive HFpEF patients (68.9 ± 12.2 years, 32.1% female) into three groups by LV hypertrophy (LVH) and enlargement (LVE) at baseline: (-)LVH/(-)LVE (n = 989), (+)LVH/(-)LVE (n = 1448), and (+)LVH/(+)LVE (n = 261). We examined temporal changes in LV structures and their prognostic impacts during a median 8.7-year follow-up. From (-)LVH/(-)LVE, (+)LVH/(-)LVE to (+)LVH/(+)LVE at baseline, the incidence of the primary outcome, a composite of cardiovascular death or HF admission, significantly increased. Among 1808 patients who underwent echocardiography at both baseline and 1 year, we noted substantial group transitions from baseline to 1 year; the transition rates from (-)LVH/(-)LVE to (+)LVH/(-)LVE, from (+)LVH/(-)LVE to (-)LVH/(-)LVE, from (+)LVH/(-)LVE to (+)LVH/(+)LVE, and from (+)LVH/(+)LVE to (+)LVH/(-)LVE were 27% (182/671), 22% (213/967), 6% (59/967), and 26% (44/170), respectively. In the univariable Cox proportional hazard model, patients who transitioned from (+)LVH/(-)LVE to (+)LVH/(+)LVE or remained in (+)LVH/(+)LVE had the worst subsequent prognosis [hazard ratio (HR) 4.65, 95% confidence interval (CI) 3.09-6.99, P < 0.001; HR 4.01, 95% CI 2.85-5.65, P < 0.001, respectively], as compared with those who remained in (-)LVH/(-)LVE. These results were unchanged after adjustment for the covariates including baseline LV ejection fraction (LVEF) and 1-year LVEF change. CONCLUSION: In HFpEF patients, LV structures dynamically change over time with significant prognostic impacts, where patients who develop LVE with LVH have the worst prognosis.
No takes yet. Share an insight, caveat, or question.
Yamanaka et al. (2020) conducted a cohort in Heart failure with preserved ejection fraction (HFpEF) (n=2,698). Transitioning to left ventricular hypertrophy and enlargement vs. Remaining without left ventricular hypertrophy or enlargement was evaluated on Composite of cardiovascular death or HF admission (HR 4.65, 95% CI 3.09-6.99, p=<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: